FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to medicinal agents, namely, to using fumaric acid amides of the formula (I): 
These compounds are used in preparing a medicinal agent designated for treatment of autoimmune diseases, response reactions "transplant against host", treatment of diseases mediated by NfkappaB, and to fumaric acid amides of the formula (I) and to a medicinal agent comprising fumaric acid amide of the formula (I) taken in the dose corresponding to 1-500 mg of fumaric acid as measured for a single dose and designated for treatment abovementioned diseases. Fumaric acid amides and a medicinal agent comprising thereof are characterized by absence of systemic adverse effect of body and resistance against hydrolysis that allows avoiding their multiply dosing.
EFFECT: valuable medicinal properties of agents.
19 cl, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USING FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC FAILURE, MYOCARDIAL INFARCTION AND ANGINA | 2007 |
|
RU2459621C2 |
| USING DERIVATIVES OF FUMARIC ACID IN TREATMENT OF CARDIAC INSUFFICIENCY AND ASTHMA | 2004 |
|
RU2313339C2 |
| DERIVATIVES OF FUMARIC ACID AS NF-kappaB INHIBITOR | 2002 |
|
RU2282440C2 |
| CYCLIC PEPTIDES WITH ANTINEOPLASTIC AND ANTIANGIOGENIC ACTIVITY | 2012 |
|
RU2603286C2 |
| METHOD OF CONJUGATING PEPTIDES, MEDIATED BY TRANSGLUTAMINASE | 2005 |
|
RU2385879C2 |
| CONJUGATED PROTEINS WITH PROLONGED ACTION IN VIVO | 2009 |
|
RU2526804C2 |
| INHIBITORS OF ANTIGEN PRESENTATION BY II CLASS MHC MOLECULES AND METHODS OF APPLICATION THEREOF | 2004 |
|
RU2333219C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| GROWTH HORMONES WITH PROLONGED EFFICACY IN VIVO | 2011 |
|
RU2605627C2 |
| OPIORPHIN PEPTIDE DERIVATIVES AS POTENTIAL INHIBITORS OF ECTOPEPTIDASES, PARTICIPATING IN DEGRADATION OF ENKEPHALINS | 2009 |
|
RU2542365C2 |
